Research programme: antibody therapies - Crucell/LFB Biotechnologies
Latest Information Update: 16 Jun 2011
At a glance
- Originator Crucell; LFB Biotechnologies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 25 Jul 2007 Preclinical trials in Undefined indication in France (unspecified route)